SCHEMBL124491

SCHEMBL124491

O=C1Nc2cc(Cl)c(Cl)cc2C1c1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.40
SLC6A3 Q01959 5/20 0.40
SLC6A4 P31645 3/20 0.40
RAB9A P51151 1/20 0.40
TP53 P04637 2/20 0.39
MDM2 Q00987 2/20 0.36
IDO1 P14902 1/20 0.35
BRD4 O60885 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MDM4 O15151 1/20 0.34
CACNB4 O00305 1/20 0.34
CACNA1A O00555 1/20 0.34
CACNA1G O43497 1/20 0.34
CACNG3 O60359 1/20 0.34
CACNA1F O60840 1/20 0.34
CACNA1H O95180 1/20 0.34
CACNB3 P54284 1/20 0.34
CACNA2D1 P54289 1/20 0.34
CACNG7 P62955 1/20 0.34
CACNA1B Q00975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7471620 0.87 BRD4 (0.46) SLC6A2SLC6A3TP53IDO1BRD4
SCHEMBL3965995 0.85 CACNB4 (0.41) SLC6A2SLC6A3SLC6A4RAB9ATP53
SCHEMBL125584 0.79 SLC6A2 (0.39) SLC6A2SLC6A3SLC6A4RAB9ATP53
SCHEMBL4589633 0.77 TSHR (0.41) SLC6A2SLC6A3TP53IDO1ALDH1A1
SCHEMBL30965341 0.76 BRD4 (0.43) RAB9ATP53MDM2BRD4ALDH1A1
SCHEMBL29242301 0.76 BRD4 (0.43) RAB9ATP53MDM2BRD4ALDH1A1
SCHEMBL29242543 0.76 TP53 (0.40) TP53MDM2ALDH1A1CACNB4CACNA1A
SCHEMBL7463659 0.75 BRD4 (0.51) TP53BRD4CACNB4CACNA1ACACNA1G
SCHEMBL3969144 0.75 TP53 (0.43) TP53MDM2ALDH1A1CACNB4CACNA1A
SCHEMBL325218 0.74 HAO1 (0.53) RAB9ATP53IDO1BRD4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103443076-B Indol-2-one derivatives disubstituted in position 3, their preparation and their therapeutic application 赛诺菲-安万特 2016-06-22 CN disclosed
CN-103443076-A Indol-2-one derivatives disubstituted in position 3, their preparation and their therapeutic application SANOFI AVENTIS 2013-12-11 CN disclosed
US-8202871-B2 Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-06-19 US disclosed
EP-2188253-B1 Indol-2-one derivatives disubstituted in 3-position, preparation thereof and therapeutic use thereof SANOFI SA (FR) 2012-03-07 EP disclosed
US-20110118280-A1 INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-05-19 US disclosed
US-20100210662-A1 INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-08-19 US disclosed
EP-2188253-A2 INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-05-26 EP disclosed
WO-2009056707-A2 INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210662-A1 INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF IDO2, IDO1, TPH2 SLC6A2 51/4885SLC6A3 50/4885SLC6A4 59/4885
US-20110118280-A1 INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF IDO2, IDO1, TPH2 SLC6A2 51/4885SLC6A3 50/4885SLC6A4 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.